Image source: The Motley Fool. Tuesday, March 17, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Joseph Burnett Chief Financial Officer — Danilo D’Alessandro Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Total 2025 Revenue -- $37,000,000, including $1,200,000 from the Eris Holdings Inc. acquisition, up from $31,400,000 in 2024. -- $37,000,000, includi...
Image source: The Motley Fool. Tuesday, March 17, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Joseph Burnett Chief Financial Officer — Danilo D’Alessandro Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Total 2025 Revenue -- $37,000,000, including $1,200,000 from the Eris Holdings Inc. acquisition, up from $31,400,000 in 2024. -- $37,000,000, including $1,200,000 from the Eris Holdings Inc. acquisition, up from $31,400,000 in 2024. Biologics and Drug Delivery Revenue -- Increased 10% to $19,000,000, driven by higher product sales as pharmaceutical partners advanced development programs. -- Increased 10% to $19,000,000, driven by higher product sales as pharmaceutical partners advanced development programs. Neurosurgery Navigation and Therapy Revenue -- Rose to $14,800,000, with $1,200,000 attributed to the EarFlo product, reflecting growth from an expanded customer base and new product launches. -- Rose to $14,800,000, with $1,200,000 attributed to the EarFlo product, reflecting growth from an expanded customer base and new product launches. Capital Equipment and Software Revenue -- $3,100,000 for the year. -- $3,100,000 for the year. Gross Margin (Full Year 2025) -- 61%, consistent with the prior year. -- 61%, consistent with the prior year. Research and Development Expense -- $13,900,000, up 12%, primarily due to $1,200,000 in higher development costs and $200,000 in additional personnel and share-based compensation. -- $13,900,000, up 12%, primarily due to $1,200,000 in higher development costs and $200,000 in additional personnel and share-based compensation. Sales and Marketing Expense -- $16,500,000, a 14% rise, driven by $1,400,000 in personnel cost increases and $900,000 related to integrating Eris, partially offset by $400,000 in lower marketing and travel expenses. -- $16,500,000, a 14% rise, driven by $1,400,000 in personnel cost increases and $900,000 related to integrating Eris, partially offset by $400,00...